Evicenter
Kisqali (ribociclib) in HR-positive HER2-negative advanced or metastatic breast cancer
Manufacturer
Novartis Pharmaceuticals Corporation
Prescribing information
Kisqali (opens in a new tab)
Questions
57
Last updated

All questions

Drug interactions: Kisqali (ribociclib) in HR-positive HER2-negative advanced or metastatic breast cancer

3 questions · 1 source

Drug interactions

What Kisqali dose is used with a strong CYP3A inhibitor?

Can Kisqali be used with tamoxifen?

Applies to Pre- and perimenopausal women with HR-positive, HER2-negative advanced or metastatic breast cancer and no prior endocrine therapy for advanced disease, with a nonsteroidal aromatase inhibitor and goserelin (MONALEESA-7)

Does Kisqali interact with letrozole, anastrozole, exemestane, or fulvestrant?